Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY: BDX )

243.68 +0.75 (+0.31%)
Streaming Delayed Price Updated: 10:23 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Becton Dickinson

< Previous 1 2 3 4 5 Next >
7 Dividend Aristocrats to Buy for Consistent Income Growth
The dividend aristocrats each provide consistent income growth over the long-term that those seeking passive income can rely on. 
Via InvestorPlace
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
These three spinoffs are already profitable. 
Via The Motley Fool
3 Stocks To Buy For Consistent Dividend Growth
One way to avoid some of the volatility in the stock market is to buy old companies that have a long history of raising dividends. These are companies with iconic brands, lasting products, and... 
Via Talk Markets
Becton, Dickinson's Debt Overview
 
Via Benzinga
(BDX) - Analyzing Becton, Dickinson's Short Interest
 
Via Benzinga
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company? 
Via News Direct
Looking Into Becton's Return On Capital Employed
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Becton, Dickinson
 
Via Benzinga
A Bullish Sign Appears On Becton, Dickinson's Chart
 
Via Benzinga
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices. 
Via Benzinga
The 7 Best Dividend Growth Stocks for Long-Term Investors
Although passive income is always useful under uncertain times, why not get capital gains through the best dividend growth stocks? 
Via InvestorPlace
Becton Dickinson Reports Cybersecurity Vulnerabilities For Alaris Infusion Monitoring Software
Becton Dickinson and Co (NYSE: BDX) issued a voluntary notification regarding cybersecurity vulnerabilities with its Alaris Infusion Central software. 
Via Benzinga
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in... 
Via Benzinga
Why Embecta Stock Popped by Nearly 13% Today
Twin beats and raised guidance make for a good day on the market for the diabetes care specialist. 
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Becton, Dickinson
 
Via Benzinga
2 Medical Stocks to Watch Heading Into 2023
The two healthcare companies easily outdid the S&P 500 this year. 
Via The Motley Fool
Embecta Stock Tumbles On Mixed Q4 Results, Softer Guidance
 
Via Benzinga
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products 
Via News Direct
Topics Economy
Exposures Supply Chain
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Sharps Technology, Inc. (NASDAQ: STSS) recently announced that the Company will be commercializing cutting-edge prefillable syringe system products to provide new solutions to customers in the... 
Via Benzinga
Becton Dickinson, Freeport-McMoRan, GXO Logistics And This Mid-Cap ETF On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named iShares Core S&P Mid-Cap ETF (NYSE: IJH), saying that "mid-c 
Via Benzinga
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Medical device company Sharps Technology, Inc. (NASDAQ: STSS) is closing out a successful year after its April initial public offering (IPO) on the NASDAQ market. The company focuses on the development... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Becton, Dickinson
 
Via Benzinga
2 Relatively Safe Dividend Stocks to Buy Today and Hold Forever
They already have extensive track records of success, and there's even more on the way. 
Via The Motley Fool
2 Top Dividend Kings to Buy for the Long Haul
No matter how much changes, these two healthcare giants keep performing. 
Via The Motley Fool
Reliable Passive Income: an Analysis on Dividend Kings
A Dividend King is any stock that has increased its dividend for 50+ cosecutive years, doubling that of a Dividend Aristocrat. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
 
Via Benzinga
NIO To $34? Plus This Analyst Sees $245 For Becton, Dickinson and Company
Piper Sandler cut the price target on Becton, Dickinson and Company (NYSE: BDX) from $255 to $245. Piper Sandler analyst Jason Bednar maintained the stock with a Neutral. Becton, Dickinson shares... 
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,700 Today
Becton, Dickinson (NYSE:BDX) has outperformed the market over the past 20 years by 3.41% on an annualized basis producing an average annual return of 11.05%. Currently, Becton, Dickinson has a market... 
Via Benzinga
Becton Dickinson's FY23 Guidance Trails Wall Street View Reflecting Foreign Currency Impact
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.